首页> 外文OA文献 >Surveillance after treatment for cervical intraepithelial neoplasia: Outcomes, costs, and cost-effectiveness
【2h】

Surveillance after treatment for cervical intraepithelial neoplasia: Outcomes, costs, and cost-effectiveness

机译:宫颈上皮内瘤变治疗后的监测:结果,成本和成本效益

摘要

Objective: To estimate outcomes and costs of surveillance strategies after treatment for high-grade cervical intraepithelial neoplasia (CIN). Methods: A hypothetical cohort of women was evaluated after treatment for CIN 2 or 3 using a Markov model incorporating data from a large study of women treated for CIN, systematic reviews of test accuracy, and individual preferences. Surveillance strategies included initial conventional or liquid-based cytology, human papillomavirus testing, or colposcopy 6 months after treatment, followed by annual or triennial cytology. Estimated outcomes included CIN, cervical cancer, cervical cancer deaths, life expectancy, costs, cost per life-year, and cost per quality-adjusted life-year. Results: Conventional cytology at 6 and 12 months, followed by triennial cytology, was least costly. Compared with triennial cytology, annual cytology follow-up reduced expected cervical cancer deaths by 73% to 77% and had an average incremental cost per life-year gained of $69,000 to $81,000. For colposcopy followed by annual cytology, the incremental cost per life-year gained ranged from $70,000 to more than $1 million, depending on risk. Between-strategy differences in mean additional life expectancy per woman were less than 4 days; differences in mean incremental costs per woman were as high as $822. In the cost-utility analysis, colposcopy at 6 months followed by annual cytology had an incremental cost per quality-adjusted life-year of less than $5,500. Human papillomavirus testing or liquid-based cytology added little to no improvement to life-expectancy with higher costs. Conclusion: Annual conventional cytology surveillance reduced cervical cancers and cancer deaths compared with triennial cytology. For high risk of recurrence, a strategy of colposcopy at 6 months increased life expectancy and quality-adjusted life expectancy. Human papillomavirus testing and liquid-based cytology increased costs, but not effectiveness, compared with traditional approaches. © 2010 by The American College of Obstetricians and Gynecologists.
机译:目的:评估高级宫颈上皮内瘤变(CIN)治疗后的监测策略的结果和成本。方法:使用马尔可夫模型对假设的女性队列进行了评估,该模型使用了马尔可夫模型,纳入了接受CIN治疗的女性的大型研究数据,测试准确性的系统评价和个人偏好,采用了马尔可夫模型。监测策略包括最初的常规或基于液体的细胞学检查,人乳头瘤病毒检测或治疗后6个月的阴道镜检查,然后进行年度或三年一次的细胞学检查。估计的结果包括CIN,子宫颈癌,子宫颈癌死亡,预期寿命,成本,每生命年的成本和每质量调整生命年的成本。结果:常规的细胞学检查在6和12个月时进行,然后进行三年一次的细胞学检查,费用最低。与三年期细胞学相比,年度细胞学随访将预期的宫颈癌死亡人数降低了73%至77%,每生命年的平均增量成本增加了$ 69,000至$ 81,000。对于阴道镜检查和随后的年度细胞学检查,根据风险的不同,每个生命年所增加的费用范围从70,000美元到超过100万美元不等。不同妇女之间的平均预期寿命之间的战略差异少于4天;每个妇女的平均增量成本差异高达822美元。在成本效用分析中,阴道镜检查在6个月后进行年度细胞学检查,每质量调整生命年的增量成本低于5500美元。人乳头瘤病毒测试或基于液体的细胞学检查对预期寿命的改善几乎没有或没有改善,但费用较高。结论:与三年期细胞学相比,年度常规细胞学监测可减少子宫颈癌和癌症死亡。对于高复发风险,阴道镜检查策略在6个月时可增加预期寿命和质量调整后的预期寿命。与传统方法相比,人乳头瘤病毒测试和基于液体的细胞学检查增加了成本,但没有效果。 ©2010,美国妇产科学院。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号